[e-drug] Johnson & Johnson Turns Its Back on AIDS Patients (2)

e-drug
1

Dear all

Now what kind of stick besides moral persuasion can get J & J to the negotiating table to talk about essentially a
market-based/oriented solution? Surely a few patents covering about 8 to
12% of BigPharma's market cannot break the innovation system (or is that
just a ruse)?

Riaz K Tayob
riaz.tayob@gmail.com

2

E-Drug: Johnson & Johnson Turns Its Back on AIDS Patients (3)
-------------------------------------------------------------

[Details of the patent pool can be found at http://www.medicinespatentpool.org where factsheets can be accessed.

" The idea behind the patent pool is that patent holders –
companies, researchers, universities and governments
– voluntarily licence their patents to the Pool under
certain conditions. The Pool then makes licences
available to qualified third parties, such as generic drug
manufacturers, which then pay appropriate royalties
on the sale of the medicines for use in developing
countries."

- moderator]

Dear Colleagues,

I wonder if anyone could remind us on the terms of the Patent Pool in relation to innovator companies (patent holders). What are the arrangements for this Pool, and what is the compelling factor to join the Pool or not? Is there a legal requirement upon industry to join the Pool, or is this a voluntary arrangement that calls for joining, based on some of the public health challenges already submitted by colleagues?

Regards,
Bonnie

Bonface Fundafunda PhD., MBA., B.Pharm
Manager, Drug Supply Budget Line
Ministry of Health,
P.O. Box 30205,
Ndeke House,
Lusaka,
Zambia
Tel: +260 211 25 41 83
Fax: +260 211 25 33 44
Mobile: + 260 979 25 29 00
Email: bcfunda@hotmail.com